Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma

Authors

Ana M. De Jesus-Acosta
Jennifer N. Durham (ORCID: https://orcid.org/0000-0001-9097-9125)
Y. J. Ding
Amol Narang (ORCID: https://orcid.org/0000-0002-0876-4967)
Arielle Urman
Meizheng Liu
Katrina Purtell (ORCID: https://orcid.org/0009-0005-7249-1894)
Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
Charmaine Waisome-Stephens
H. Qi
Richard Burkhart
Elizabeth Thompson
Dung Le
Lei Zheng
Elizabeth Jaffee
Daniel Laheru
Jin He

Institutions

The University of Texas MD Anderson Cancer Center (US)
Johns Hopkins University (US)
The University of Texas at San Antonio Health Science Center (US)
Johns Hopkins Medicine (US)
Sidney Kimmel Cancer Center (US)
Sidney Kimmel Comprehensive Cancer Center (US)

Publication Details

Journal: Frontiers in Immunology
Published: 2026-03-09
DOI: https://doi.org/10.3389/fimmu.2026.1715761
Primary Topic: Pancreatic and Hepatic Oncology Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Eli Lilly and Company
Johns Hopkins University

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma

Ana M. De Jesus-Acosta, Jennifer N. Durham, Y. J. Ding, Amol Narang et al.

Mar 9, 2026

Frontiers in Immunology

Pancreatic and Hepatic Oncology Research

article

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma

Ana M. De Jesus-Acosta, Jennifer N. Durham, Y. J. Ding, Amol Narang, Arielle Urman, Meizheng Liu, Katrina Purtell, Hao Wang, Charmaine Waisome-Stephens, H. Qi, Richard Burkhart, Elizabeth Thompson, Dung Le, Lei Zheng, Elizabeth Jaffee, Daniel Laheru, Jin He

March 9, 2026article en

Abstract

No abstract available for this paper.

Frontiers in ImmunologyVol. 17

The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), The University of Texas at San Antonio Health Science Center (US), Johns Hopkins Medicine (US), Sidney Kimmel Cancer Center (US), Sidney Kimmel Comprehensive Cancer Center (US)

Eli Lilly and Company, Johns Hopkins University

Good health and well-being

Openalex Percentile: Top 28%

Pancreatic and Hepatic Oncology Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma — Ana M. De Jesus-Acosta, Jennifer N. Durham, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS